MARKET

OPK

OPK

Opko Health
NASDAQ
1.230
+0.020
+1.65%
After Hours: 1.240 +0.01 +0.80% 19:48 02/13 EST
OPEN
1.220
PREV CLOSE
1.210
HIGH
1.270
LOW
1.210
VOLUME
2.14M
TURNOVER
--
52 WEEK HIGH
2.035
52 WEEK LOW
1.110
MARKET CAP
944.27M
P/E (TTM)
-5.1101
1D
5D
1M
3M
1Y
5Y
1D
Opko Health Inc. to Report Fourth Quarter and Full-Year 2025 Financial Results
Reuters · 2d ago
Opko Health: Expanding Pipeline and Strategic Partnerships Underpin Buy Rating and Long-Term Value Upside
TipRanks · 5d ago
Weekly Report: what happened at OPK last week (0202-0206)?
Weekly Report · 5d ago
Opko Health Entera Bio, Entera Bio expand partnership to advance PTH tablet
TipRanks · 02/04 13:16
OPKO Health Expands Partnership With Entera Bio To Advance First-in-Class Oral Long Acting PTH Tablet
Benzinga · 02/04 13:05
OPKO HEALTH AND ENTERA BIO EXPAND PARTNERSHIP TO ADVANCE FIRST-IN-CLASS ORAL LONG ACTING PTH TABLET FOR PATIENTS WITH HYPOPARATHYROIDISM
Reuters · 02/04 13:05
Steve Rubin Joins Entera Bio Board as Gerry Ostrov Steps Down
Reuters · 02/04 13:00
Steve Rubin wird neues Vorstandsmitglied bei Entera Bio Ltd
Reuters · 02/04 13:00
More
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.